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Analyzing Pain Medication Use and Adherence in Patients with Myotonic
Dystrophy and Facioscapulohumeral Dystrophy
Abstract
Objectives: Myotonic dystrophy (DM) and facioscapulohumeral dystrophy (FSHD) are two of the most
common muscular dystrophies in adults. It has been reported that patients with these two disorders may
suffer from pain and inadequate pain management. The purpose of this study is to analyze the current use of
pain medications and develop a survey to assess pain medication use and adherence in this patient population.
Methods: Patients registered in the National Registry for DM and FSHD at the University of Rochester were
surveyed on pain medication use and the most significant problem of their disease. After analysis of these
surveys, an additional survey was created that contained questions specifically on pain medication use,
adherence, and general questions about the patients’ pain. Questions for the survey were devised from
previous studies on medication adherence, questionnaires on medication adherence and beliefs, and
questions from the Brief Pain Inventory.
Results: In the first survey, pain medication was used by 34% of the survey respondents (n=519/1527).
Specifically, NSAIDs were used by 23.5% and opioids were used by 4% of survey respondents. In a separate
survey, pain was reported as the most burdensome problem by 8% of patients (n= 27/355). This was greater
than problems related with balance (n=10/355), fatigue (n=20/355), or gastrointestinal distress (n=8/355).
Conclusion: Despite the low reported response that pain was the most significant problem associated with
their disease, the prevalence of pain medication use indicates that further study into the impact of pain and
pain medication use in this patient population is warranted. Specifically, investigating questions about
adherence, use, and beliefs toward pain medication will lead to an increased understanding of pain and its
treatment in this patient population. This knowledge can lead to the ability of pharmacists to optimize pain
management and to reduce adverse reactions to pain medications.
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Analyzing pain medication use and adherence in patients with
myotonic dystrophy and facioscapulohumeral dystrophy
Bryan P. Fitzgerald, Amy L. Parkhill, PhD
St. John Fisher College, Wegmans School of Pharmacy, Rochester, NY
Myotonic dystrophy (DM) and facioscapulohumeral dystrophy
(FSHD) are the two most common adult muscular dystrophies.1,2 A
National Registry was created at the University of Rochester
Medical Center to connect muscular dystrophy patients and family
members with research opportunities.3
Pain is a symptom that many patients in this population have
experienced – 64% of DM patients and 82% of FSHD patients are
said to experience pain.4 Levels and locations of pain vary, although
back pain is most common.4,5 Pain can be a problematic and
debilitating symptom for patients, so it is important to understand
the impact of pain on DM and FSHD patients and how it’s managed.
1. Ghr.nlm.nih.gov [Internet]. Maryland:  U.S. National Library of Medicine®; c2013 [updated 2014 Apr 21; cited 2014 Apr 24] Available from:   
http://ghr.nlm.nih.gov/condition/facioscapulohumeral-muscular-dystrophy.
2. Ghr.nlm.nih.gov [Internet]. Maryland:  U.S. National Library of Medicine®; c2013 [updated 2014 Apr 21; cited 2014 Apr 24] Available from: 
http://ghr.nlm.nih.gov/condition/myotonic-dystrophy
3. Hilbert JE, Kissel JT, Luebbe EA, et al; Registry Scientific Advisory Committee.  (2012).   If you build a rare disease registry, will they enroll and will
they use it? Methods and data from the National Registry of DM and FSHD.  Contemp Clin Trials.  33(2):302-11.
4. Jensen, MP, Hoffman, AJ, Stoelb BL, et al. Chronic pain in persons with myotonic dystrophy and facioscapulohumeral dystrophy. (2008). Arch Phys Med 
Rehabil. 89:320-328.
5. Abresch, RT, Carter GT, Jensen MP, Kilmer DD. Assessment of pain and health-related quality of life in slowly progressive neuromuscular disease. 
(2002). American Journal of Hospice & Palliative Care. 19(1):39-48.
6. Hudson TJ, Edlund MJ, Steffick DE, et al. Epidemiology of regular prescribed opioid use: results from a national, population-based survey. (2008). 
Journal of Pain Symptom Management. 36(3):280-8. Available from: http://www.ncbi.nlm.nih.gov/ pubmed/18619768.
7. Food & Drug Administration. McNeil Consumer & Specialty Pharmaceuticals (McNeil). (2002). [cited 2013 Sep 20]. Available from: 
http://www.fda.gov/ohrms/dockets/ ac/02/briefing/3882B2_02_McNeil-NSAID.htm
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Table 1. Most significant problems of disease for FSHD and DM 
(DM1, DM2, and DM-unknown) patients
Patients registered in the National Registry for DM and FSHD at the
University of Rochester are surveyed on medication use upon
enrollment into the Registry (n=1527). In a separate survey
(n=371), patients were asked about the most significant problem of
their disease. Data was collected anonymously over the course of
several months.
After analysis of these surveys, an additional 73-question survey
was created containing questions on basic disease and pain
information, pain medication adherence factors, beliefs on pain
medication, specific questions on opioids and NSAIDs, and pain
medication counseling. The survey was approved by SJFC IRB and
the registry’s Scientific Advisory Board and it will be electronically
sent to eligible participants in the registry in May 2015.
Methods
Of the 371 total responses, pain ranked as the 5th most significant
problem out of the 12 main problems reported, with 28 responses
(Table 1). In DM patients, pain was the 3rd most significant
problem, tied with mobility issues with 15 responses.
Table 2 shows pain medication use in 1527 surveyed patients. Of
these patients, 34% used some sort of pain medication, 23.5% used
non-steroidal anti-inflammatory drugs (NSAIDs), and 4% used
opioids.
FSHD
(n = 194)
DM
(n = 177)
Total
(n = 371)
Muscle weakness 94 84 178
Mobility 41 15 56
Disease progression 28 7 35
Muscle loss 28 7 35
Pain 13 15 28
Fatigue 3 17 20
Balance 3 9 12
Cardiac 1 9 10
Gastrointestinal 1 7 8
Psychiatric 0 6 6
Respiratory/Speech 2 4 6
Genetic 0 3 3
FSHD
(n = 575)
DM
(n = 952)
Total
(n = 1527)
Opioid use 38 23 61 (4.0%)
NSAID use 162 197 359 (23.5%)
Pain medication use 239 280 519 (34.0%)
Conclusion
Despite pain only ranking 5th in the most significant problem
associated with their disease, it was still found to be more
significant than other commonly-reported problems including
fatigue, GI distress, and balance. The prevalence of pain medication
use indicates that further studies relating to pain and the use of
pain medications in this patient population are warranted. It can be
concluded that DM and FSHD patients use NSAIDs less than the
general population (23.5% vs. 37.5%) and use opioids more than
the general population (4% vs. 2%).6,7 Specifically, investigating
questions about adherence, use, and beliefs toward pain
medication will lead to an increased understanding of pain and its
treatment in this patient population.
Table 2. Pain medication, opioid, and NSAID use in FSHD and DM 
(DM1 and DM2) patients
